TKT Replagal "complete review"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Transkaryotic Therapies receives "complete review" letter Nov. 22 for its Fabry disease therapy Replagal (agalsidase alfa). FDA has continuing concerns regarding efficacy with the enzyme replacement therapy and will seek input from the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 14. Preliminary results from an 80-patient Phase III trial did not show a statistically significant difference from placebo for the primary renal function endpoint. TKT suggests six months was not long enough to show renal benefi
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.